株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

コンパニオン診断 (CDx) の世界市場:2018年〜2028年

The Companion Diagnostics (CDx) Market Forecast 2018-2028: Leading Companies, Trends and Developments in the Growing Theranostics Market

発行 Visiongain Ltd 商品コード 210220
出版日 ページ情報 英文 183 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=139.15円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
コンパニオン診断 (CDx) の世界市場:2018年〜2028年 The Companion Diagnostics (CDx) Market Forecast 2018-2028: Leading Companies, Trends and Developments in the Growing Theranostics Market
出版日: 2018年04月10日 ページ情報: 英文 183 Pages
概要

世界におけるコンパニオン診断市場は、2023年に146億ドルに達する見込みで、さらに2028年まで安定した成長を記録すると予測されています。この市場成長を促進する要因として、細胞および組織研究の進歩、規制状況の改善、各地での政府援助の強化、そしてまだ満たされない医療ニーズ分野における新たな治療法がいくつか発表されたことなどが挙げられます。

当レポートでは、コンパニオン診断 (CDx) の世界市場について調査し、個別化医療および体外診断検査 (IVD検査) におけるコンパニオン診断の位置付け、コンパニオン診断の市場規模の推移と予測、コンパニオン診断のひとつとしてのセラノスティクスの成長、主要国の動向、主な上市済み製品とパイプラインにおける提携の動向、コンパニオン診断開発のビジネスモデル、競合環境、主要企業のプロファイルなどをまとめています。

Figure 4.20 The South Korean CDx Market Forecast Revenue ($bn) and AGR (%) 2017-2028

第1章 レポート概要

第2章 コンパニオン診断:イントロダクション

  • 個別化医療の基盤
  • 個別化医療:患者治療のパラダイムの変化
  • 体外診断検査 (IVD検査)
    • コンパニオン診断:IVDのひとつのタイプ
    • コンパニオン診断とセラノスティクスの違い
    • バイオマーカーとコンパニオン診断
    • ゲノムバイオマーカー
    • 癌のゲノムバイオマーカー
  • 関連法規制
  • コンパニオン診断の同時期の開発の奨励

第3章 世界のコンパニオン診断市場

  • 範囲と限界
  • 世界のコンパニオン診断市場:実績
  • 世界のコンパニオン診断市場:売上予測
  • コンパニオン診断:他のIVD部門を上回る成長
  • コンパニオン診断:IVD市場でシェアを伸ばす
  • 部門別市場の実績
  • セラノスティクス:コンパニオン診断の中の最速成長部門
  • コンパニオン診断の主要部門のシェアの変化の見通し

第4章 コンパニオン診断:主要国市場の予測

  • 主要国市場:主要3市場が主導する現状
  • 主要国の売上予測
    • 市場シェアの変化の予測
  • 米国の売上予測
  • EU5カ国の実績
    • 売上予測
    • シェアの変化
    • ドイツの売上予測
    • フランスの売上予測
    • イタリアの売上予測
    • スペインの売上予測
    • 英国の売上予測
  • 日本の売上予測
  • 中国の売上予測
  • インドの売上予測
  • ブラジルの売上予測
  • ロシアの売上予測
  • 韓国の売上予測
  • その他の売上予測

第5章 コンパニオン診断市場:上市済み製品とパイプラインの提携

  • バイオマーカー:コンパニオン診断開発の中心
  • 米国FDA承認済みコンパニオン診断検査
  • 癌の診断:コンパニオン診断のR&Dパイプラインの対象として引き続き主流
  • 高額な癌治療がCDxの開発を推進
  • コンパニオン診断/製薬事業者の提携

第6章 コンパニオン診断:ビジネスモデルとステークホルダー

  • コンパニオン診断開発のビジネスモデル
  • コンパニオン診断市場への参入の推進因子
  • コンパニオン診断市場に影響力を持つステークホルダー
  • コンパニオン診断市場における競合状況

第7章 主要企業

  • Roche:診断市場の世界的リーダー
  • Qiagen N.V.:製薬事業者にとってのCDxの主要な提携先
  • Abbott Molecular:確立された競合事業者
  • Agilent Technologies (Dako)
  • Myriad Genetics
  • BioMerieux
  • Thermo Fisher Scientific

第8章 定量分析

  • SWOT分析
  • 強み
  • 弱み
  • 機会
  • 脅威
  • ポーターのファイブフォース分析

第9章 総論

  • 概要
  • セラノスティクス:急成長の市場
  • コンパニオン診断の主要企業
  • 製薬/診断会社との提携モデル
  • コンパニオン診断を推進する主要治療領域としての癌
  • コンパニオン診断市場の商業的成長推進因子
  • コンパニオン診断市場の商業的成長阻害因子
  • まとめ

第10章 用語集

目次
Product Code: PHA0300

What can be expected from the Companion Diagnostics market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2028, assessing data, trends, opportunities and prospects there.

Our 183-page report provides 127 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole companion diagnostics market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2018-2028 and other analyses show you commercial prospects

Besides revenue forecasting to 2028, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porterús Five Forces analysis) and commercial developments.

The report also includes will find revenue forecasts to 2028 for the following submarkets in the companion diagnostics market:

  • Theranostics
  • Other Companion Diagnostics

Additionally, this report includes a forecast to 2026 for the global in vitro diagnostics market.

The report also includes will find revenue forecasts to 2028 for the following national and regional markets for companion diagnostics:

  • US
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Japan
  • China
  • India
  • Russia
  • Brazil
  • South Korea

image1

The report provides detailed profiles of key companies operating within the companion diagnostics market:

  • F. Hoffmann-La Roche Ltd
  • Qiagen N.V.
  • Abbott Laboratories
  • Agilent Technologies
  • Myriad Genetics
  • bioMerieux
  • Thermo Fisher Scientific

Leading companies and potential for market growth

Overall revenue for the Companion Diagnostics market will reach $14.60n in 2023, our work forecasts. We predict strong revenue growth through to 2028. Advances in cellular and tissue research, an improving regulatory landscape, strong support from governments in multiple regions and the launch of several new therapies in areas of unmet clinical need will drive sales to 2028.

Our work analyses the key companies in the market. See visiongainús analysis of 7 leading companies, including these:

  • F. Hoffmann-La Roche Ltd
  • Qiagen N.V.
  • Abbott Laboratories
  • Agilent Technologies
  • Myriad Genetics
  • bioMerieux
  • Thermo Fisher Scientific

A company profile gives you the following information where available:

  • Discussion of a companyús activities and outlook
  • Historic revenue, analysis and discussion of company performance over the past 5 years
  • Analysis of major products currently on the market
  • Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the companion diagnostics industry?

Our new report discusses issues and events affecting the companion diagnostics market. You will find discussions, including qualitative analyses:

  • Highly diverse market needing strong knowledge of key therapeutic indications
  • Changing regulatory landscape challenging new entrants and major market players alike
  • Emerging therapies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Companion Diagnostics: Market Forecast 2018-2028 report helps you

In summary, our 183-page report gives you the following knowledge:

  • Revenue forecasts to 2028 for the Companion Diagnostics market - discover the industryús prospects, finding promising places for investments and revenues
  • Revenue forecasts to 2028 for each major submarket - discover prospects for leading companion diagnostics products in the following areas: theranostics and other companion diagnostics.
  • Revenue forecasts to 2028 for twelve leading national markets - US, Germany, France, Italy, Spain, UK, Japan, China, India, Russia, Brazil and South Korea
  • Assessment of 7 leading companies - analysis of products, revenue, mergers & acquisitions, sales by region and products
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongainús study is for everybody needing commercial analyses for the companion diagnostics market and leading companies. You will find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 The Companion Diagnostics Market Overview
  • 1.2 Companion Diagnostics Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. Introduction to Companion Diagnostics

  • 2.1 The Foundation of Personalised Medicine
  • 2.2 Personalised Medicine: Changing the Patient Treatment Paradigm
  • 2.3 In Vitro Diagnostic (IVD) Tests
    • 2.3.1 Companion Diagnostics: A Type of IVD
    • 2.3.2 Differences between Companion Diagnostics and Theranostics
    • 2.3.3 Biomarkers to Companion Diagnostics
    • 2.3.4 Genomic Biomarkers
    • 2.3.5 Genomic Oncology Biomarkers
  • 2.4 Regulations in the Companion Diagnostics Market
    • 2.4.1 FDA's Final Guidance on Companion Diagnostics
    • 2.4.2 LDTs: A Changing Landscape
  • 2.5 Encouraging the Contemporaneous Development of Companion Diagnostics

3. The World Companion Diagnostics Market, 2017-2028

  • 3.1 Scope and Limitations
  • 3.2 The Global Companion Diagnostics Market, 2016 and 2017
  • 3.3 The Global Companion Diagnostics Market Sales Forecast, 2017-2028
  • 3.4 Companion Diagnostics: Growth Outpacing the Rest of the IVD Market
  • 3.5 Companion Diagnostics: Increasing Market Share of the IVD Market
  • 3.6 The Companion Diagnostics Market by Submarket, 2017
  • 3.7 Theranostics: Fastest Growing Segment of the CDx Market
  • 3.8 Changing Market Shares of the Leading Companion Diagnostics Submarkets, 2017-2028

4. Leading National Markets for Companion Diagnostics, 2017-2028

  • 4.1 The Leading National Markets for Companion Diagnostics: Led by 3 Dominant Markets in 2017
  • 4.2 The Leading National Markets for Companion Diagnostics Sales Forecast, 2017-2028
    • 4.2.1 Changing Market Shares of Leading National Markets, 2017-2028
  • 4.3 The US Companion Diagnostics Market Sales Forecast, 2017-2028
    • 4.3.1 The US Will Continue to Dominate the Market
  • 4.4 The EU5 Companion Diagnostics Sales Market, 2017
    • 4.4.1 The EU5 Companion Diagnostics Market Sales Forecast, 2017-2028
    • 4.4.2 Changing Market Shares of the EU5 Companion Diagnostics Market
    • 4.4.3 The German Companion Diagnostics Market Sales Forecast 2017-2028
    • 4.4.4 The French Companion Diagnostics Market Sales Forecast, 2017-2028
    • 4.4.5 The Italian Companion Diagnostics Market Sales Forecast, 2017 2028
    • 4.4.6 The Spanish Companion Diagnostics Market Sales Forecast, 2017-2028
    • 4.4.7 The UK Companion Diagnostics Market Sales Forecast, 2017-2028
  • 4.5 The Japanese Companion Diagnostics Market Sales Forecast, 2017-2028
    • 4.5.1 Japanús Medical Technology Regulatory Process Reducing Time to Market
  • 4.6 The Chinese Companion Diagnostics Market Sales Forecast, 2017-2028
    • 4.6.1 Cancer Rates will Drive Adoption of Companion Diagnostic Tests
  • 4.7 The Indian Companion Diagnostics Market Sales Forecast, 2017-2028
  • 4.8 The Brazilian Companion Diagnostics Market Sales Forecast, 2017-2028
  • 4.9 The Russian Companion Diagnostics Market Sales Forecast, 2017-2028
  • 4.10 The South Korean Companion Diagnostics Market Sales Forecast, 2017-2028
  • 4.11 The Rest of the World Companion Diagnostics Market Sales Forecast, 2017-2028

5. The Companion Diagnostics Market: Marketed Products and Pipeline Partnerships

  • 5.1 Biomarkers: At the Forefront of Companion Diagnostics Development
  • 5.2 US FDA Approved Companion Diagnostic Tests, 2016
  • 5.3 Oncology Continues to Dominate the R&D Pipeline of Companion Diagnostics
  • 5.4 Expensive Cancer Therapies Encourages the Development of CDx
  • 5.5 Companion Diagnostic/Pharma Partnerships, 2013-2014

6. Business Models and Stakeholders in the Companion Diagnostics Market

  • 6.1 Business Models for the Development of Companion Diagnostics
    • 6.1.1 The Partnership Model is the Most Practiced Method
    • 6.1.2 The Stand-Alone Model: Licensing an IP
    • 6.1.3 The One Stop Shop Model: An Approach by Big Pharma
    • 6.1.4 Using Contract Diagnostics Organisations (CDO): An Emerging Trend
  • 6.2 Factors Driving Companies to Enter the Companion Diagnostics Market
  • 6.3 Stakeholders Influencing the Companion Diagnostics Market
    • 6.3.1 Pharmaceutical Companies and Diagnostic Manufacturers
    • 6.3.2 Regulatory Authorities
    • 6.3.3 Testing Laboratories
    • 6.3.4 Physicians and Patients
    • 6.3.5 Payers
  • 6.4 Companion Diagnostics Competitive Landscape, 2017

7. Leading Companies in the Companion Diagnostics Market 2017

  • 7.1 Roche: Global Diagnostics Leader
    • 7.1.1 Ventana Medical Systems (Roche)
    • 7.1.2 Sales and Recent Performance Analysis, 2016
    • 7.1.3 Roche Diagnostics by Region, 2016
    • 7.1.4 Roche: Growing Diagnostic Portfolio
    • 7.1.5 Approval of Ventana and Cobas EGFR Mutation Test V2
    • 7.1.6 Rocheús Portfolio of Companion Diagnostic Project Pipeline and Marketed Companion Diagnostics, 2017
    • 7.1.7 Ventana Companion Diagnostics: Robust New Prototype Assays
    • 7.1.8 Recent Companion Diagnostic External Collaborations, 2014-2017
      • 7.1.8.1 Roche/Ariosa Diagnostics and Signature Diagnostics
      • 7.1.8.2 Loxo Oncology/ Roche: Larotrectinib Pan-TRK IHC Companion Diagnostic
      • 7.1.8.3 CAPP Medical/ Roche: Development for Diagnostic Operating Segment
      • 7.1.8.4 GENEWEAVE and Kapa Acquisitions Help Cement Rocheús Position as the Market Leader
      • 7.1.8.5 Foundation Medicine/Roche
      • 7.1.8.6 MedImmune (AstraZeneca)/Ventana: Assay for NSCLC Targeted Clinical Trials
      • 7.1.8.7 Merck/Ventana: CDx for an Undisclosed Target
      • 7.1.8.8 AstraZeneca/Roche: CDx to Support Target Drug AZD9291
      • 7.1.8.9 Boehringer Ingelheim/Roche
      • 7.1.8.10 ImmunoGen/ Ventana
  • 7.2 Qiagen N.V.: Leading CDx Collaborator with Pharmaceutical Companies
    • 7.2.1 Sales and Recent Performance Analysis, 2012-2016
    • 7.2.2 Qiagen Sales by Region
    • 7.2.3 Qiagenús Portfolio of Marketed Companion Diagnostics, 2016
    • 7.2.4 Companion Diagnostics Collaboration Agreements with Pharma, 2016
      • 7.2.4.1 Collaboration with Therawis Diagnostics
      • 7.2.4.2 Collaboration with HTG Molecular Diagnostics
      • 7.2.4.3 Collaboration with Array BioPharma
      • 7.2.4.4 Collaboration with Singulex
      • 7.2.4.5 Strategic Acquisitions
  • 7.3 Abbott Molecular: An Established Competitor
    • 7.3.1 Sales and Recent Performance Analysis, 2014-2016
    • 7.3.2 Abbott Molecular: Expansive Oncology Biomarker Pipeline
    • 7.3.3 Recent Collaborations
      • 7.3.3.1 Collaboration with Celgene and Agios
      • 7.3.3.2 Collaboration with AstraZeneca
      • 7.3.3.3 Collaborative Efforts with Idera
  • 7.4 Agilent Technologies (Dako)
    • 7.4.1 Life Sciences and Diagnostics Business
    • 7.4.2 Agilent Life Sciences and Diagnostics, Sales and Recent Performance Analysis, 2016
    • 7.4.3 Agilent: Next Generation Sequencing Platforms
    • 7.4.4 Recent Companion Diagnostic Approvals
      • 7.4.4.1 Expanded FDA Approval for the Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Gastric or Gastroesophageal Junction (GEJ) Cancer
      • 7.4.4.2 Agilent/ Bristol- Myers Squibbús: Companion Diagnostic Approvals
      • 7.4.4.3 Agilent/Pfizer/Merck: An Ongoing Collaboration
    • 7.4.5 Strategic Acquisitions
      • 7.4.5.1 Acquisition of i-Lab Solutions
      • 7.4.5.2 Acquisition of Multiplicom
  • 7.5 Myriad Genetics
    • 7.5.1 Acquisition of Myriad RBM: Increases the Companyús Market Share of Companion Diagnostics
    • 7.5.2 Companion Diagnostic Service Offerings
    • 7.5.3 Sales and Recent Performance Analysis, 2016
      • 7.5.3.1 myRisk: Next Generation Hereditary Cancer Testing
    • 7.5.4 Myriad Genetics Recent Collaborations
      • 7.5.4.1 Myriad/BeiGene: Collaboration Agreement
      • 7.5.4.2 Myriad/AstraZeneca: Complementary Diagnostic FDA Approvals
      • 7.5.4.3 Acquisition of /Sividone Diagnostics
      • 7.5.4.4 Acquisition of Assurex Health
      • 7.5.4.5 Collaboration with AbbVie
  • 7.6 BioMérieux
    • 7.6.1 Sales and Recent Performance Analysis, 2016
    • 7.6.2 Sales by Region, 2016
    • 7.6.3 Sales by Technology, 2016
    • 7.6.4 Companion Diagnostics: Recent M&A Activity & Collaboration
      • 7.6.4.1 Strategic Acquisitions
      • 7.6.4.2 Collaboration with Banyan Biomarkers
      • 7.6.4.3 Agreement with Astute Medical to Distribute Nephrocheck
      • 7.6.4.4 Mergers, Acquisitions and Collaborations
    • 7.6.5 bioTheranostics: Subsidiary for Oncology Diagnostics
  • 7.7 Thermo Fisher Scientific
    • 7.7.1 Sales and Recent Performance Analysis, 2014-2016
      • 7.7.1.1 Thermo Fisher Scientific Sales by Region, 2016
    • 7.7.2 Recent Collaborations and Acquisitions
      • 7.7.2.1 Thermo Fisher Scientific/Seegene-FDA Clearances
      • 7.7.2.2 Thermo Fisher Scientific/University Hospital Basel
      • 7.7.2.3 Acquisition of Alfa Aesar
      • 7.7.2.4 Affymetrix: Thermo Fisherús Next Target
      • 7.7.2.5 Thermo Fisher Scientific Collaboration with Pfizer and Novartis to Offer NGS-Based Companion Test for NSCLC

8. Qualitative Analysis of the Companion Diagnostics Market, 2017-2028

  • 8.1 SWOT Analysis of the Companion Diagnostics Market
  • 8.2 Strengths
    • 8.2.1 A CDx Strategy Decreases the Length of Approval Process
    • 8.2.2 Premium Prices for Companion Diagnostics
    • 8.2.3 A CDx Development Strategy Can Generate More Effective Drugs
    • 8.2.4 Therapeutics Tied with CDx can have Safer Profiles
    • 8.2.5 Reducing the Cost of Healthcare
    • 8.2.6 Increased Regulatory Scrutiny on Marketed Drugs
    • 8.2.7 Targeted Therapies Will Drive the CDx Market
  • 8.3 Weaknesses
    • 8.3.1 Reimbursement Challenges
    • 8.3.2 Lack of Clear Regulatory Guidelines
    • 8.3.3 Capital Intensity is High
  • 8.4 Opportunities
    • 8.4.1 Fast-growing Emerging Markets
    • 8.4.2 Next Generation Sequencing
    • 8.4.3 Many New CDx/ Pharma Company Partnerships
  • 8.5 Threats
    • 8.5.1 Complex Business Models and Business Partnerships
    • 8.5.2 Medical Device Excise Tax
  • 8.6 Porterús Five Forces Analysis of the Companion Diagnostics Market
    • 8.6.1 Rivalry Among Competitors [High]
    • 8.6.2 Power of Suppliers [High]
    • 8.6.3 Power of Buyers [Medium]
    • 8.6.4 Threat of New Entrants [Medium]
    • 8.6.5 Threat of Substitutes [High]

9. Conclusions

  • 9.1 Overview
  • 9.2 Theranostics: A Fast Growing Market
  • 9.3 Leading Companion Diagnostic Companies
  • 9.4 Pharmaceutical/Diagnostic Partnership Model
  • 9.5 Oncology is the Leading Therapy Area Driving Companion Diagnostics
  • 9.6 Commercial Drivers of the Companion Diagnostics Market
  • 9.7 Commercial Restraints of the Companion Diagnostics Market
  • 9.8 Concluding Remarks

10. Glossary

  • Associated Reports
  • Visiongion Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain Report Evaluation Form

Table of Tables

  • Table 1.1 The CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2017-2023
  • Table 1.2 The CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2023-2028
  • Table 2.1 Examples of Clinically Relevant Cancer Biomarkers, 2016
  • Table 3.1 The World IVD Market: Revenue ($bn) and Market Share (%) by Segment, 2017
  • Table 3.2 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 3.3 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 3.4 The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 3.5 The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 3.6 CDx Market Share (%) in the IVD Market, 2017, 2023, 2028
  • Table 3.7 The World Companion Diagnostics Market: Revenue ($bn) and Market Share (%) by Submarket, 2017
  • Table 3.8 The World Companion Diagnostics Market by Submarket: Revenue ($bn), AGR (%) and CAGR (%), by Submarket, 2017-2023
  • Table 3.9 The World Companion Diagnostics Market by Submarket: Revenue ($bn), AGR (%) and CAGR (%), by Submarket, 2023-2028
  • Table 3.10 Revenue ($bn) and Market Share (%) of Submarkets in the CDx Market, 2017, 2023, 2028
  • Table 4.1 The Leading National Markets for CDx: Sales ($m), Market Share (%), 2017
  • Table 4.2 The Leading National Companion Diagnostics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2023
  • Table 4.3 The Leading National Companion Diagnostics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2023-2028
  • Table 4.4 Revenue ($bn) and Market Share (%) of the National Markets in the CDx Market, 2017, 2023, 2027
  • Table 4.5 The US CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2017-2023
  • Table 4.6 The US CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2023-2028
  • Table 4.7 The EU5 CDx Market Forecast: Revenue ($bn) and Market Share (%), 2017
  • Table 4.8 The EU5 Companion Diagnostic National Market Forecasts: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.9 The EU5 Companion Diagnostic National Market Forecasts: Revenues ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.10 Market Share (%) of Each EU5 Region in the CDx Market, 2017, 2023, 2027
  • Table 4.11 The German CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 4.12 The German CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 4.13 The French CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.14 The French CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.15 The Italian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.16 The Italian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.17 The Spanish CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.18 The Spanish CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.19 The UK CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.20 The UK CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.21 The Japanese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2017-2023
  • Table 4.22 The Japanese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2023-2028
  • Table 4.23 The Chinese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.24 The Chinese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.25 The Indian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.26 The Indian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.27 The Brazilian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.28 The Brazilian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2027-2028
  • Table 4.29 The Russian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.30 The Russian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.31 The South Korean CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.32 The South Korean CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.33 The Rest of the World CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.34 The Rest of the World CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 5.1 List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018
  • Table 5.2 (Contúd) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018
  • Table 5.3 (Contúd) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018
  • Table 5.4 (Contúd) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018
  • Table 5.5 (Contúd) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018
  • Table 5.6 List of Cleared or Approved Companion Diagnostic Devices and Their Complementary Therapeutic Drug, 2015-2017
  • Table 5.7 List of CDx Diagnostic/Pharma Partnerships, 2015-2017
  • Table 6.1 List of Companies in the Companion Diagnostics Market, 2017
  • Table 6.2 (Contúd) List of Companies in the Companion Diagnostics Market, 2017
  • Table 7.1 Roche Diagnostics: Revenue ($bn) and Revenue Share (%) by Business Area, 2016
  • Table 7.2 Roche Diagnostics: Revenue ($bn), Revenue Shares (%) by Region, 2016
  • Table 7.3 Roche: Instruments/devices planned for 2017
  • Table 7.4 Roche: Tests/Assays planned for 2017
  • Table 7.5 Roche Diagnostics: List of Marketed Companion Diagnostics, 2017
  • Table 7.6 Qiagen: Revenue ($bn), Net Income ($bn) and Profit Margin, 2012-2016
  • Table 7.7 Qiagen: Revenue ($m), Revenue Share (%) by Geography, 2014-2016
  • Table 7.8 Qiagen: Marketed Molecular Diagnostic Products, 2016
  • Table 7.9 Qiagenús Molecular Diagnostics by Therapeutic Area, 2016
  • Table 7.10 Abbott: Revenue ($bn) by Segment, 2014-2016
  • Table 7.11 Abbott Molecular: Biomarker Pipeline, 2017
  • Table 7.12 Agilent Technologies: Revenue ($bn) by Business Segment 2014-2016
  • Table 7.13 Myriad Genetics: Biomarker Product Portfolio, 2016
  • Table 7.14 Myriad Genetics: Revenue ($bn) by Segment, FY ended June 2015- FY ended June 2017
  • Table 7.15 bioMérieux : Revenue (€bn), ($bn) and AGR (%), 2012-2016
  • Table 7.16 bioMérieux: Revenue Share (%) by Technology, 2016
  • Table 7.17 Thermo Fisher Scientific: Revenue ($bn) and Market Share (%)
  • Table 7.18 Thermo Fisher Scientific: Revenue ($bn), Revenue Share (%) by Geography, 2016
  • Table 8.1 SWOT Analysis of the Companion Diagnostics Market, 2017-2028
  • Table 9.1 Theranostics and Other In Vitro Diagnostics: Global Sales Forecast ($bn), 2017, 2023 and 2028

Table of Figures

  • Figure 1.1 Companion Diagnostics: Overview of Submarkets
  • Figure 2.1 Development of Biomarkers into Companion Diagnostics, 2018
  • Figure 3.1 The World IVD Market: Market Share (%) in the IVD Market, 2017
  • Figure 3.2 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Figure 3.3 The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Figure 3.4 The World CDx Market Share (%) in the IVD Market, 2023
  • Figure 3.5 The World CDx Market Share (%) in the IVD Market, 2028
  • Figure 3.6 The World Companion Diagnostics Market: Market Share (%) by Submarket, 2017
  • Figure 3.7 The World CDx Market by Submarket: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 3.8 The World CDx Market Share (%) in the IVD Market, 2023
  • Figure 3.9 The World CDx Market Share (%) in the IVD Market, 2028
  • Figure 4.1 The Leading National Markets for CDx by Sales ($bn), 2017
  • Figure 4.2 The Leading National Markets for CDx by Market Share (%), 2017
  • Figure 4.3 The Leading National Markets for CDx by Market Share (%), 2023
  • Figure 4.4 The Leading National Markets for CDx by Market Share (%), 2027
  • Figure 4.5 The US CDx Market Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 4.6 The EU5 Leading National Markets for CDx by Revenue ($bn), 2017
  • Figure 4.7 The EU5 Leading National Markets for CDx by Market Share (%), 2017
  • Figure 4.8 The EU5 National Markets for CDx by Market Share (%), 2023
  • Figure 4.9 The EU5 National Markets for CDx by Market Share (%), 2028
  • Figure 4.10 The German CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.11 The French CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.12 The Italian CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.13 The Spanish CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.14 The UK CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.15 The Japanese CDx Market Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 4.16 The Chinese CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.17 The Indian CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.18 The Brazilian CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.19 The Russian CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.20 The South Korean CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.21 The Rest of the World CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 6.1 Current Business Models for the Development of Companion Diagnostics, 2017
  • Figure 6.2 Stakeholders in the Companion Diagnostics Market, 2017
  • Figure 7.1 Roche Diagnostics: Revenues ($bn) by Business Area, 2016
  • Figure 7.2 Roche Diagnostics: Revenue Share (%) by Business Area, 2016
  • Figure 7.3 Roche Diagnostics: Revenue Share (%) by Geography, 2016
  • Figure 7.4 Qiagen: Revenue ($bn) and Net Income ($bn), 2012-2016
  • Figure 7.5 Qiagen: Revenue Share (%) by Geography, 2016
  • Figure 7.6 Abbott Laboratories: Historical Revenue ($bn), 2013-2016
  • Figure 7.7 Abbott Laboratories: Revenue Share (%) by Business Sector, 2016
  • Figure 7.8 Agilent Technologies: Revenue ($bn) by Business Segment 2014-2016
  • Figure 7.9 Myriad Genetics: Segment Share (%), 2016
  • Figure 7.10 bioMérieux: Revenue ($bn) and AGR (%), 2012-2016
  • Figure 7.11 bioMérieux: Revenue by Region (%), 2016
  • Figure 7.12 bioMérieux: Revenue Share (%) by Technology, 2015
  • Figure 7.13 Thermo Fisher Scientific: Revenue Sales (%) by Business Sector, 2016
  • Figure 7.14 Thermo Fisher Scientific: Revenue Share (%) by Geography, 2016
  • Figure 8.1 Drivers and Restraints in the Companion Diagnostics Market, 2017-2028
  • Figure 8.2 Porterús Five Analysis of the Companion Diagnostics Market, 2017-2028
  • Figure 9.1 Theranostics and Other In Vitro Diagnostics: World Sales Forecast ($bn), 2017, 2023 and 2028

Companies Listed

  • 20/20 Gene Systems
  • Abbott Diagnostics
  • Abbott Molecular
  • Affymetrix
  • Agilent (Dako)
  • Almac
  • Ambry Genetics
  • Amgen
  • Arca bipharma
  • Arno
  • Astellas Pharma
  • AstraZeneca
  • Asuragen
  • Bayer
  • Biogenex Laboratories, Inc.
  • bioMérieux
  • Biomonitor
  • Boehringer Ingelheim
  • Brain Resource Company
  • Bristol-Myers Squibb
  • Cancer Research UK
  • CancerGuide Diagnostics
  • Caprion Proteomics
  • Caris Life Sciences
  • Celera (acquired by Quest Diagnostics)
  • Celgene
  • Cepheid
  • ChemGenex Pharmaceuticals
  • Clarient
  • Clinical Reference Laboratory
  • Clovis
  • College of American Pathology (CAP)
  • CompanDx
  • Crescendo Bioscience
  • Curidium Medica
  • Dako (Agilent)
  • Deloitte
  • DiagnoCure
  • Dx assays
  • DxS
  • Eli Lilly
  • Endocyte
  • European Medicines Agency (EMA)
  • Exosome Diagnostics
  • Ferring
  • Flagship Biosciences
  • FlowMetric Diagnostics
  • Foundation Medical
  • Foundation Medicine
  • Genentech
  • Genfit
  • Genia Technologies
  • Genmab
  • GenMark Diagnostics
  • Gilead Sciences
  • GlaxoSmithKline
  • GSK
  • Hexie Health
  • HistologiX
  • Idera
  • Illumina
  • ImmunoGen
  • Incyte
  • InDex Pharmaceuticals
  • IntegraGen
  • Inverness Medical Innovations (now known as Alere)
  • Invivoscribe Technologies
  • Ipsen
  • Ipsogen
  • IQuum
  • Janssen Pharmaceutical
  • Kimball Genetics (a division of LabCorp)
  • Kunlun Health Insurance
  • Lab Corp
  • Lab21
  • Laboratory for Personalized Molecular Medicine
  • Leica
  • Leica Biosystems
  • Leica Micosystems
  • Life Technologies
  • Medical Research Council
  • Medicare
  • MedImmune (AstraZeneca)
  • Merck
  • Merck Serono
  • MolecularMD
  • Monogram Biosciences
  • Myriad Genetics
  • Myriad RBM
  • Nanosphere
  • Nanostring
  • NanoString Technologies
  • National Health Insurance (NHI) (South Korea)
  • NIH
  • Northern Institute for Cancer Research
  • Novartis
  • Oxford BioTherapeutics (earlier Oxford Genome Sciences)
  • Pacific Diagnostics Clinical Laboratory (ResearchDx)
  • Pfizer
  • PICC Health Insurance
  • Ping An Insurance Group
  • Prionics
  • Progenika Biopharma
  • Prometheus
  • Protagen
  • Protagen Diagnostics
  • Qiagen
  • Quintiles
  • Quintiles Transnational Corporation
  • Randox Pharma Services
  • ResearchDx
  • Resonance Health
  • Resonance Health Analysis Services
  • RiboMed Biotechnologies
  • Roche
  • Rule-Based Medicine
  • Saladax Biomedical
  • ServizioSanitarioNazionale (SSN)
  • Siemens
  • Siemens Healthcare
  • Signal Genetics
  • Sirius Genomics
  • Sistema Único de Saúde (SUS)
  • Skyline Diagnostics
  • Solvay Innogenetics
  • Sysmex Inostics
  • Takedaús Millennium unit
  • Target Discovery
  • TcLand Expression
  • TESARO
  • The Association of British Pharmaceutical Industries
  • The Food and Drug Administration (FDA)
  • The Haute Autorité de santé (HAS)
  • The National Institute for Health and Care Excellence (NICE)
  • Theranostics (NZ)
  • Theranostics Health
  • Thermo Fisher
  • Thermo Fisher Scientific
  • Third Wave Technologies (Hologic)
  • TIB MolBiol
  • Tocagen
  • Tragara Pharmaceuticals
  • Transgenomic
  • TRICARE
  • TrimGen Corporation
  • Tufts Center for the Study of Drug Development
  • Unilabs
  • University of Newcastle
  • Ventana Medical Systems (a subsidiary of Roche)
  • ViiV Healthcare
  • Weisenthal Cancer Group
Back to Top